A comparison study was conducted to evaluate the cost effectiveness of surfactant replacement therapy in the treatment of hyaline membrane disease (HMD).
Study population included neonates admitted because of HMD severe enough to require assisted ventilation with FiO2 greater that 0.4 per cent.
This group (n=44) was compared with the outcome for neonates treated in the same centre 1 year before surfactant became available (n=39).
Comparison between the two groups was made in relation to cost of care depending on the duration of hospitalization.
The duration of hospitalization in the survivors of the treated group was shorter (P=0.06) ; accordingly, the cost of care was less.
A savings of US $11,880 per patient survived in the treated group was expected, the nationwide financial impact of this treatment modality is discussed.
Mots-clés Pascal : Membrane hyaline maladie, Traitement, Surfactant pulmonaire, Analyse coût efficacité, Arabie Saoudite, Asie, Economie santé, Hospitalisation, Etude comparative, Nouveau né, Homme, Etude statistique, Prématuré, Appareil respiratoire pathologie, Poumon pathologie, Détresse respiratoire, Nouveau né pathologie
Mots-clés Pascal anglais : Hyaline membrane disease, Treatment, Pulmonary surfactant, Cost efficiency analysis, Saudi Arabia, Asia, Health economy, Hospitalization, Comparative study, Newborn, Human, Statistical study, Premature, Respiratory disease, Lung disease, Respiratory distress, Newborn diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0386442
Code Inist : 002B20G03. Création : 12/09/1997.